California-based biotechnology company Gilead Sciences has developed a promising candidate for a vaccine against the 2019 novel coronavirus, which worked against the infection in both animals and a human patient during tests.Original Article
You may also like
The Great RIF(T): One FDA Division’s Destruction and...
More on the Impact of the FDA RIFs: How Information...
Court Rejects Challenge to DEA ALJ Hearing Authority...
Déjà Vu: OPDP Again Targets Provider Branded Website...
ASCA 2024 Performance Update: Can ASCA Improve...
Enforcement Under the New FDA: HPM to Host a Q&A...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.